x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012921
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding residues surrounding Gln370 of human TP/ECGF1. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TYMP |
| UniProt No. | P19971 |
| Gene ID | 1890 |
| Gene Description | Thymidine phosphorylase is a platelet-derived endothelial cell growth factor that catalyzes the formation of thymine and 2-deoxy-D-ribose-1-phosphate from thymidine and orthophosphate. This intracellular enzyme is capable of both promoting angiogenesis and inhibiting apoptosis. Thymidine phosphorylase catalytic activity is required for its angiogenic function. Increased expression of TP/PD-ECGF is seen in a wide variety of different solid tumors and inflammatory diseases and is often associated with poor prognosis. Alternatively, TP can activate fluorouracil derivative prodrugs and increase the antitumor activity of the related treatment. The use of thymidine phosphorylase as a cancer therapeutic target has been studied extensively, with emphasis on either inhibiting TP enzymatic activity or increasing enzyme induction with concomitant DFUR treatment. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
